Scribd Logo
Upload

Welcome to Scribd!

  • 47 views

    Slide 1

    Uploaded by

    marwa

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd

    Slide 1

    Uploaded by

    marwa
    47 views6 pages

    Original Title

    Slide 1.docx

    Copyright

    © © All Rights Reserved

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    47 views6 pages

    Slide 1

    Uploaded by

    marwa

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    of 6

    Slide 1

    Sanofi mission statement is to


    provide potentially life-changing
    treatments and the protection of
    life-saving vaccines to millions
    of people, and affordable access
    to it’s medicines in some of the
    world’s poorest countries.

    Bargaining power of supplier Slide 2


    Sanofi buys it’s raw material
    from numerous suppliers, in
    addition to Sanofi created
    EUROAPI for API
    manufacturing.
    .
    Threat of new entrants
    New entrants in Drug
    Manufacturers - Major brings
    innovation, and put pressure on
    Sanofi through lower pricing
    strategy, reducing  costs, and
    providing new value propositions
    to the Customers.
    Bargaining power of buyer
    Sanofi supplies to 128 countries
    (hospitals, Distributers, public
    organizations, pharmacist).
    Threat of substitutes

    Sanofi has 91
    projects in
    clinical
    development
    34 of these
    projects in
    phase 3 or
    submitted to
    regulatory
    authorities for
    approval.
    Pipeline highlights: 7 positive
    pivotal read-out. 10 new
    molecules. 5 basket studies. 8
    major approval.
    Rivalry
    Sanofi faces intense competition
    from both local and multinational
    companies. Some of these
    competitors include AstraZeneca
    (AZN), Regeneron
    Pharmaceuticals (REGN),
    Vertex(VRTX), Bristol-Myers
    Squibb (BMY) and many more
    all of whom are competing for a
    share of the pharmaceutical
    market.
    -

    * Sanofi has three operating Slide 3


    segments: Pharmaceuticals,
    Vaccines, and Consumer
    Healthcare. The
    Pharmaceuticals segment
    comprises, for all
    geographical territories, the
    commercial operations of
    the following global
    franchises: Specialty Care
    (Dupixent® , Neurology &
    Immunology, Rare
    Diseases, Oncology, and
    Rare Blood Disorders) and
    General Medicines (Core
    Assets and Non-Core
    Assets), together with
    research, development and
    production activities
    dedicated to the
    Pharmaceuticals segment.
    This segment also includes
    associates whose activities
    are related to
    pharmaceuticals. The
    Vaccines segment
    comprises, for all
    geographical territories, the
    commercial operations of
    Sanofi Pasteur, together
    with research, development
    and production activities
    dedicated to vaccines. The
    Consumer Healthcare
    segment comprises, for all
    geographical territories, the
    commercial operations for
    Sanofi’s Consumer
    Healthcare products,
    together with research,
    development and
    production activities
    dedicated to those products.

    * Sanofi Manufacturing Slide 4


    System, which is based
    on major regional
    manufacturing hubs
    that make products
    primarily for their
    region while having the
    capacity to supply other
    regions. Combined with
    a common culture of
    industrial excellence.
    * The entire industrial
    network continues its
    digital transformation
    to ensure agility, higher
    productivity, efficiency
    and sustainable
    manufacturing.
    * In addition, Sanofi
    created EUROAPI, a
    new European company
    for the development,
    production and
    marketing of active
    pharmaceutical
    ingredients (APIs).

    * Access to Slide 5

    healthcare
    Innovation
    Patient safety
    * Contribute to
    WHO
    partnership to
    fight neglected
    tropical
    diseases.
    * Invested in
    R&D to fight
    malaria,
    tuberculosis and
    lashmania.
    * Plans to remove
    all plastic blister
    packs for its
    syringe vaccines
    by 2027. In
    addition,
    committed to
    eco-designing
    all new products
    by 2025. To
    reduce
    greenhouse gas
    emissions by
    55% by 2030,
    all Sanofi sites
    will use 100%
    electricity from
    renewable
    sources and
    have also set a
    target of carbon
    neutrality for car
    fleet, both by
    2030.
    * Ensuring that
    under-
    represented
    employees have
    an equal chance
    to succeed by
    focusing on
    access to
    opportunities
    and addressing
    their specific
    needs 

    You might also like